• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Dicerna Pharmaceuticals

edit

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutic agents in various disease areas based on dicer substrate technology platform. The company offers RNA interference (RNAi)-targeted drugs and delivery systems for therapeutic areas of oncology and metabolic diseases. It also provides Dicer Substrate Technology, a second generation of gene silencing, which triggers RNAi and is used in therapeutic areas, including inflammation, immunology, and cardiovascular diseases. The company was founded in 2007 and is based in Watertown, Massachusetts.

Milestones

edit

• 
  Dicerna Pharmaceuticals added Jim Jenson as CEO.
  Posted 1/5/10 at 2:39am
• 
  Dicerna Pharmaceuticals received $4M in Series B funding. (10/21/10)
  Posted 10/22/10 at 7:01pm via masshightech.com
• 
  Dicerna Pharmaceuticals received $25M in Series B funding. (8/11/10)
  Posted 8/11/10 at 11:12am via fiercebiotech.com
• 
  Dicerna Pharmaceuticals received $124M in Venture Round funding. (1/4/10)
  Posted 1/5/10 at 2:58am via fiercebiotech.com
• 
  Dicerna Pharmaceuticals — Dicerna wins $5M payment from partner KHK. (12/15/11)
  Posted 12/15/11 at 7:44pm via masshightech.com
• 
  Dicerna Pharmaceuticals — Dicerna Pharmaceuticals Inc. and Japanese biopharmaceutical firm Kyowa Hakko Kirin Co. Ltd. have expanded a collaboration deal the two companies share, to include immunologic and inflammatory disease areas. (12/7/10)
  Posted 12/8/10 at 8:50am via masshightech.com

Videos

Screenshots

edit

Above: Home Page
Uploaded: 1/5/10

Sources

1. Dicerna lands $124M RNAi development pact (fiercebiotech.com) [edit]
2. Dicerna bags $25M Series B for next-gen RNAi work Read more: Dicerna bags $25M Series B for next-gen RNAi work - FierceBiotech http://www.fiercebiotech.com/story/dicerna-bags-25m-series-b-next-gen-rnai-work/2010-08-11?utm_medium=rss&utm_source=rss#ixzz0w (fiercebiotech.com) [edit]
3. Dicerna makes $29M second close on Series B funding round (masshightech.com) [edit]
Dicerna deal with Japanese biotech adds new drug target (masshightech.com) [edit]
Dicerna wins $5M payment from partner KHK (masshightech.com) [edit]